Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has requested that pharma companies marketing glucagon-like peptide-1 receptor agonists ...
SILVER SPRING, Md. — The U.S. health regulator asked drugmakers on Tuesday to remove warnings about a potential risk of suicidal thoughts from widely used GLP-1 weight loss drugs, including Novo ...
Add Yahoo as a preferred source to see more of our stories on Google. The FDA has asked drugmakers to remove warnings about potential risk of suicidal thoughts from GLP-1 drugs including Novo ...
・The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior. ・The agency conducted a large meta-analysis of 91 placebo-controlled clinical ...
The FDA is requesting that drugmakers remove suicidal ideation and behavior warnings from the labeling of three GLP-1 receptor agonists — Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound ...
Federal regulators on Tuesday told drugmakers Novo Nordisk and Eli Lilly to remove label warnings about potential suicidal thoughts and behaviors from their blockbuster weight-loss medications. The ...
Regulator asks drugmakers to remove warnings of suicidal thoughts from GLP-1 drugs' labels FDA finds no link between GLP-1 drugs and suicidal thoughts Novo Nordisk and Eli Lilly welcome FDA's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results